Eli Lilly's retatrutide trial data shows a 2.2% A1C reduction and up to 21% weight loss, significantly outpacing Novo Nordisk's Ozempic in a key head-to-head study for type 2 diabetes treatment.
Eli Lilly's retatrutide has demonstrated superior clinical efficacy in the TRANSCEND-T2D-2 Phase 3 trial, achieving a 2.2% A1C reduction compared to 1.8% for Ozempic. Furthermore, the drug showed significant weight loss superiority, with participants losing between 20% and 21% of their body weight, more than doubling the 9% weight loss observed in the Ozempic 2 mg cohort.
Retatrutide showed a 2.2% A1C reduction compared to 1.8% for Ozempic, and induced 20-21% weight loss compared to 9% for Ozempic.
The clinical data from the TRANSCEND-T2D-2 trial presents a direct competitive challenge to Novo Nordisk's Ozempic franchise. By demonstrating significantly higher weight loss and improved glycemic control, retatrutide threatens to capture market share from Novo Nordisk's established GLP-1 products in the type 2 diabetes and obesity treatment segments.
The primary threat is the superior clinical performance of Eli Lilly's retatrutide, which outperformed Ozempic in both weight loss and A1C reduction in a head-to-head Phase 3 trial.
Eli Lilly's experimental drug retatrutide demonstrated superior efficacy in a head-to-head Phase 3 trial against Novo Nordisk's Ozempic. Patients treated with retatrutide achieved significantly higher A1C reductions and more than double the weight loss compared to the 2 mg dose of Ozempic over an 80-week period.
In the TRANSCEND-T2D-2 trial, retatrutide outperformed Ozempic 2 mg by delivering higher A1C reductions and more than double the weight loss over 80 weeks.